Cumulating evidence has showed that insulin-like growth factor (IGF) signaling plays an important role in survival of patients with embryonal rhabdomyosarcoma [29,30], and thus, humanized monoclonal antibodies and small kinase inhibitors have been evaluated in many preclinical studies [31,32]. Here, IGF1 is linked to embryonal rhabdomyosarcoma.